UK and 4 nations to fast-track modified COVID-19 vaccines
Regulators in the U.K. and four other countries plan to fast-track the development of modified COVID-19 vaccines to ensure drugmakers are able to move swiftly in targeting emerging variants of the disease
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Regulators in the U.K. and four other countries plan to fast-track the development of modified COVID-19 vaccines to ensure that drugmakers are able to move swiftly in targeting emerging variants of the disease.
Previously authorized vaccines that are modified to target new variants “will not need a brand new approval or ‘lengthy’ clinical studies,” Britain’s Medicines and Healthcare Products Regulatory Agency said in a statement.
The new guidance was issued jointly by regulators in the U.K., Australia, Canada, Singapore and Switzerland. The guidelines build on the model already used to modify the flu vaccine in response to continual changes in that virus.
Under the new rules, developers will be required to provide “robust evidence” that modified COVID-19 vaccines produce a strong immune response to the variant, as well as data showing they are safe and meet quality standards.
“Our priority is to get effective vaccines to the public in as short a time as possible, without compromising on safety,” Dr. Christian Schneider, the MHRA’s chief scientific officer said in a statement. “Should any modifications to authorized COVID-19 vaccines be necessary, this regulatory approach should do that.”
The announcement comes amid concerns that a variant first discovered in Brazil may be more resistant to existing vaccines than other variants. The U.K. has banned direct flights from 33 countries in an effort to prevent variants of concern from becoming established in Britain.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.